BioSpace News Archive

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Truvada for HIV prevention in uninfected adults, a strategy called pre-exposure prophylaxis (PrEP), is well ...

Genoox, today announced it closed a $6 million funding round.

Verastem, Inc. (NASDAQ: VSTM) today announced that it has commenced a registered underwritten public offering of $35 million of its shares of common stock.

TapImmune Inc. (NASDAQ: TPIV) (“TapImmune”) today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. (“Marker”), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.

Xpert® Carba-R now FDA-cleared to aid clinicians in determining appropriate therapeutic strategy for pure colony specimens

Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) (“Intec” or “the Company”) today announces financial results for the three months ended March 31, 2018 and provides a corporate update.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), today reported financial results for the first quarter and provided a review of recent accomplishments and anticipated upcoming milestones.

First quarter 2018 revenue of $152 million

UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today announces the signature of an exclusive license agreement for the antibiotics mecillinam and pivmecillinam with LEO Pharma A/S.

A statistically significantly greater percentage of patients treated with galcanezumab also achieved at least a 50 percent reduction in weekly cluster headache attacks compared to placebo at Week 3